Cardiff Oncology (NASDAQ:CRDF) Stock Price Up 1.5%

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) shot up 1.5% on Tuesday . The company traded as high as $2.15 and last traded at $2.08. 728,089 shares changed hands during trading, a decline of 40% from the average session volume of 1,205,936 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Cardiff Oncology in a report on Monday, May 6th.

Cardiff Oncology Trading Up 8.2 %

The company has a 50 day moving average price of $3.15 and a 200 day moving average price of $3.05. The company has a market capitalization of $100.62 million, a price-to-earnings ratio of -2.50 and a beta of 1.94.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, May 2nd. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.11 million. Cardiff Oncology had a negative return on equity of 54.54% and a negative net margin of 6,594.92%. Equities analysts predict that Cardiff Oncology, Inc. will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in CRDF. Vanguard Group Inc. grew its stake in shares of Cardiff Oncology by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after purchasing an additional 9,468 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Cardiff Oncology during the first quarter worth $1,351,000. Blair William & Co. IL grew its stake in shares of Cardiff Oncology by 32.4% during the first quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock worth $919,000 after purchasing an additional 42,180 shares during the period. Callan Capital LLC grew its stake in shares of Cardiff Oncology by 37.2% during the first quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock worth $228,000 after purchasing an additional 11,600 shares during the period. Finally, PFG Investments LLC acquired a new stake in shares of Cardiff Oncology during the first quarter worth $53,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.